1Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, 2JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagara, Mysuru 570015, Karnataka, India
Email: vkguptajss@gmail.com
Received: 09 Jan 2015 Revised and Accepted: 08 Feb 2015
Change is inevitable in a pharmaceutical manufacturing operation. Vendors change processes, sources, and specifications for raw materials, equipment requires repair, service, or replacement, manufacturing locations are changed, batch sizes are increased or decreased and advancements in technology are made that dictate changes to the operations. After issuing of Marketing Authorization and/or manufacturing, many changes occurs across the Product lifecycle, i.e. Scaling up of pilot batch into commercial batch and variation in manufacturing processes, excipients and manufacturing sites. All these changes are considered as post approval changes or variations. These variations need to be approved by the respective regulatory authorities of a country. If not, it puts the marketing authorization holder and/or license holder at risk. Proper management of changes is critical and proper change management reduces the risk of suspension of licenses and the warning letter from the regulatory authorities. The present review provides an industry perception on Change Control system and importance of the Quality Management System.
Keywords: Marketing Authorization, Post Approval Changes, Marketing Authorization Holder.
Change is an inevitable phenomenon especially in the pharmaceutical industry where, with an advent of technology and knowhow, machines and manufacturing processes tend to change over a period of time in efforts to improve manufacturing and operating efficiencies.
The question “How can we update or change the information in an approved application?” is often asked. The answer varies (the batch sizes needs to change, there are new methodologies and specifications developed, we want to manufacture and test at a different site, etc.). These changes are called “post approval changes” (PACs) because they effect applications that have already been approved [1].
Changes in the Pharmaceutical system are entirely different from the deviation.
Table 1: Comparison between change control and deviation
Change control | Deviation |
Change control is a strategic activity to bring about changes in document/process/method. It can be for the smaller period of time or it can be long term usable. It must be informed to all the concerned departments for official approval of Change Control. | Deviation is an aberration from the given procedure which is done pre-plannedor accidently. A deviation can be divided into critical & non critical. Effects of critical deviations should be accessed through investigation CAPA |
Deviation is defined as “Any non-compliance of an established GMP standard or of approved requirements, specifications and standard operating procedures. Deviations need to be documented, evaluated and when appropriate, investigated in order to determine the originating causes to prevent recurrence” [2].
There are many different circumstancestouse the term “deviation”. No well-established definitions were found in the various regulatory documents in the USA or the EU. The terms used by these authorities are not always the same (for example, deviation, discrepancy, a typical situation, nonconformity). Therefore, it is authoritative for a company to define internally, what is deviation? in order to avoid ambiguity and possible mistakes concerning workflows and responsibilities [3].
Examples for potential deviations in different areas are listed in table 1 [3].
Table 2: Examples of potential deviations
Production process | Machines, plants, equipment, facilities, and media (including laboratory) | Quality control |
|
|
|
Change can come from many different directions, experience has proven that change(s) within a critical compliance and quality system will have the largest impact. The following are some area which is the sources for change: [4].
Potential changes during development and post commercialization [4].
Regulations | Vendors |
Customer requests/complaints | Facility |
Personnel | Validation |
Technology | Research |
Testing methodology | Development |
Table 3: Changes during product development & post commercialization
Particular | Changes |
Formulation | Composition: Percentage of active and inactive ingredients per unit dose |
Active Pharmaceutical Ingredient (API) | Alternate manufacture |
Altered impurity profile | |
Physical characteristic | |
New manufacturing process | |
New raw starting materials(s) excipients | |
Official grade change | |
New raw starting materials(s) excipients | |
Official grade change | |
Raw material change | |
Equipment | Bench scale |
Pilot plant | |
Biobatch | |
Scale batches | |
Commercial size | |
Continuous improvement | |
Process optimization | |
Repairs and maintenance | |
Cleaning Procedures | Manual to automated |
Equipment configuration changes | |
Manufacturing Process | Critical parameter changes |
Operating range changes | |
Optimal condition changes | |
Scale-up | |
Technology transfer | |
Rework/reprocessing procedure | |
Analytical Method Development | Qualified method |
Validated method | |
Optimize and/or modernize method | |
Customize a compendial method | |
Stability Profile | Container closure system(s) |
Storage conditions | |
Expiry period | |
Facilities | Controlled environment requirements |
Preventative maintenance | |
Emergency repairs | |
Validated classified areas | |
Structural changes | |
Cross contamination prevention | |
General housekeeping and sanitation | |
Cleaning agents and pest control | |
Critical utilities | |
Critical utilities | Clean steam |
Potable and purified water systems | |
HVAC systems | |
Compressed air system | |
Dust collection system | |
Emergency repairs to critical utilities | |
Changes in PM maintenance schedule | |
Natural disasters | Facility changes |
Utility changes | |
Validated system changes | |
Personnel turnover and loss | |
Critical components | Containers |
Closures | |
Labeling | |
Packaging materials | |
Inserts | |
Desiccants | |
Vials | |
Tubes | |
Changes to any critical parameters of these components must be monitored |
A formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect the validated status of facilities, systems, equipment or processes. The intent is to determine the need for action that would ensure and document that the system is maintained in a validated state. Paragraph is the definition [6].
History of change management [7]Change Management as a discipline initiated to emerge in the 1980s motivated by top consulting organizations working with Fortune 50 organizations. Initial adopters, like as GE, Ford, and AT&T, were very large companies that might derive important savings through more competently applying new packages and were accustomed to cutting edge thought management roles. This work resulted in early Change Management models such as GE’s Change Acceleration Process (CAP) and John Kotter’s Eight Step Process for Leading Change. At the moment, Change Management offerings were typically accessible through consulting services, with a limited number of books and textbooks available.
During the 1990s, industries undergoing important and fast change in areas such as information technology and human resources began highlighting the benefits of Change Management programs on a wider scale. The practices, consequences, and prices of applying change without anorganizedmethod has helped staff and companiesembrace Change Management tools. Though use of Change Management was still incomplete primarily to large corporations in the habit of regularly utilizing specialized consulting firms, Change Management was getting more and more perceptibility and reliability.
The 2000’s marked extensive acceptance of Change Management as a business competency for leading change. This alteration improved the reliability of Change Management in the commercial world and with project teams. The benchmarking data on ‘use of a methodology’ shows a noticeable increase from 34% in 2003 to 72% in 2011. The value of Change Management was further validated through additional research on the impact of Change Management on business success by Prosci, IBM and McKinsey.
The market for Change Management tools and training grew fast through this period, with as many as 320 accessing firms recognized as offering Change Management facilities by 2011. Some were recognized with their own Change Management procedures while others, that previously only offered consulting services, also provided exercise and some level of product offerings as well.
Benefits of change management process [8]As per EU GMP: “A formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect the validated status of facilities, systems, equipment or processes. The intent is to determine the need for action that would ensure and document that the system is maintained in a validated state” [6].
EU GMP also provides notes regarding handling of the Changes: “Significant amendments to the manufacturing process, including any change in equipment or materials, which may affect product quality and/or the reproducibility of the process, should be validated” [9].
21 CFR 211.100 and 21 CFR 211.160 is also provides two brief notes on “Change Control”
211.100 Written Procedures; deviations: “There shall be written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Such procedures shall include all requirements in this subpart. These written procedures, including any changes, shall be drafted, reviewed, and approved by the appropriate organizational units and reviewed and approved by the quality control unit” [10].
211.160 General Requirements: “The establishment of any specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms required by this subpart, including any change in such specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms, shall be drafted by the appropriate organizational unit and reviewed and approved by the quality control unit.
The requirements in this subpart shall be followed and shall be documented at the time of performance. Any deviation from the written specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms shall be recorded and justified” [11].
As per the Pharmaceutical Inspection Convection and Pharmaceutical Inspection Co-operation Scheme (PIC/S)
Change Management: Written procedures should be in place to describe the actions to be taken if a change is proposed to a starting material, product component, process equipment, process environment (or site), method of production or testing or any other change that may affect product quality or reproducibility of the process. Change control procedures should ensure that sufficient supporting data are generated to demonstrate that the revised process will result in a product of the desired quality, consistent with the approved specifications [12].
Change Control: “Change control is an important element in any Quality Assurance system. Written procedures should be in place to describe the actions to be taken if a change is proposed to a product component, process equipment, process environment (or site), method of production or testing or any other change that may affect product quality or support system operation” [13].
ResponsibilitiesProcess Owner/Principle Investigator [14]
Quality Unit [14]
Process owner/Principle Investigator and quality unit [15]
Every technical change with major impact should be assessed at least by the process owner and/or principal investigator and the quality unit.
They should decide about the measures to be taken to document the change appropriately.
Functional Group Responsibilities [1].
Table 4: Functional group responsibilities
Initiation of Change Control | Proofreading | Conformance to regulation (cGMP) and applicability to other system | Review and Approval | Regulatory Impact and Worldwide Filling Strategy | Validation | |
Quality Assurance | - | |||||
Quality Control | - | - | - | - | ||
Manufacturing | - | - | - | - | ||
Process Engineering | - | - | - | - | ||
Technical Services | - | - | - | - | ||
Regulatory Affairs | - | - | - | |||
Owner of System or procedure being changed | - | - | - | - |
Management system to direct and control a pharmaceutical company with regard to quality; the elements described below might be, required in part under regional GMP regulations. These four elements are:
Change management system [16]
Innovation, continual improvement, the outputs of process performance and product quality monitoring and CAPA drive change. In order to evaluate, approve and implement these changes properly, a company should have an effective change management system.
There is generally a difference in formality of change management processes prior to the initial regulatory submission and after submission, where changes to the regulatory filing might be required under regional requirements.
The change management system ensures continual improvement is undertaken in a timely and effective manner. It should provide a high degree of assurance there are no unintended consequences of the change.
The change management system should include the following, as appropriate for the stage of the lifecycle:
Application of Change Management System throughout the Product Lifecycle:
Table 5: Application of change management system
Pharmaceutical development | Technology transfer | Commercial manufacturing | Product discontinuation |
Change is an inherent part of the development process and should be documented; the formality of the change management process should be consistent with the stage of pharmaceutical development. | The change management system should provide management and documentation of adjustments made to the process during technology transfer activities. | A formal change management system should be in place for commercial manufacturing. Oversight by the quality unit should provide assurance of appropriate science and risk based assessments. | Any changes after product discontinuation should go through an appropriate change management system. |
Process of change control [13]
“Commitment of the company to control change to premises, supporting utilities, materials, equipment and processes used in the manufacture of medicinal products is essential to ensure a continued validation status of the systems concerned. This commitment should be stated in the relevant company documentation. For example, the Quality Manual, Quality Policy Documents or the Validation Master Plan; as part of its Quality Management System the company should have a defined and formalized Change Control Procedure.”
Flowchart 1: Process of change management system [1]
Procedure for change control process at Company and/or Sponsor Level
Following procedure is applies for both GMP [14]
“All changes should be formally requested, documented and accepted by representatives of production, QC/QA, R&D, Engineering and Regulatory Affairs as appropriate. The likely impact (risk assessment) of the change on the product should be evaluated and the need for, and the extent of Re-validation discussed. The change control system should ensure that all notified or requested changes are satisfactorily investigated, documented and authorized”[13].
“All changes that may affect product quality or reproducibility of the process should be formally requested, documented and accepted. The likely impact of the change of facilities, systems and equipment on the product should be evaluated, including risk analysis. The need for, and the extent of, re-qualification and re-validation should be determined.”
Change control requires a written procedure (change control program) to regulate at least the following points: [5]
Changes requiring control are generally documented in the form of a change request, in which the applicant for the change proposes the type of grade/evaluation of the change, specifies the time frames and measures for carrying out the change, and requests that and the change is authorized or declined by the change control committee. The documentation for the change procedure should prove that the change was evaluated (risk analysis) and the subsequently defined measures were implemented as predetermined [5].
Post approval change management protocolA post-approval change management protocol describes specific changes that a company would like to implement during the lifecycle of the product and how these would be prepared and verified. It is a step-wise approach in the assessment of changes, which allows an early evaluation of the strategy for the change and a later separate evaluation of the data produced based on the agreed strategy. Such a stepwise approach is expected to lead to faster and more predictable implementation of changes post-approval, since the MAH will have obtained agreement from the Regulatory Authorities about the proposed strategy and tests to verify the effect of the change on product quality [15].
Content of the change management protocol [15]
In general, in order to support the proposed change, the company should submit all relevant information that can demonstrate that it has acquired adequate knowledge to prepare and manage the impact of the change.
The content of the protocol could include the following, depending on the nature of the change [15].
The report must contain information about the formulation, including justification for any and all Changes made in the methods during the development process. Additionally, the report will include information about the following [4].
The entire purpose of this change control report is to point the authority toward a document that delineates the science and technology that went into making the product and that includes all preliminary studies right up to the regulatory submission stage.
CONCLUSIONIn the current study, it is affirmed that in the pharmaceutical industry, change control does not mean the elimination of any change; it means the systematic control of changes to ensure the changes made do not have any adverse impact on the safety, quality, purity, or potency of the pharmaceutical product. Changes made in a pharmaceutical manufacturing plant that has any potential to impact the safety, quality, purity, efficacy, or potency of a pharmaceutical preparation must be made in a way that assures these characteristics are not adversely impacted. Because of the highly globalized level of the modern pharmaceutical industry, implementing the change in the system and/or operation is not as simple as it would seem. With the advances in science and technology that we have witnessed over the decades, it is opinioned that a balance must be struck in order to properly utilize all of the tools available to improve living conditions and address health problems across the globe.
It is obvious that management of post approval changes is a multidimensional task and calls for many different actions and strategies which need to be aligned with national laws and international treaties and practices. Post Approval Changes in GMP level are seriously influenced by the market needs, market response and so on. In other words, trade and commerce considerations are important in the management of post approval changes.
Different forms of changes demand different treatment, handling, planning, and strategies and engagement of persons with different domain knowledge such as life science, engineering, medicines, pharmaceutical regulatory professional and marketing. Each industry should evolve its own change control policies, management style, strategies, etc. Depending on its area of specialty.
CONFLICT OF INTERESTS
Declared None
REFERENCES